Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa

Ingrid V Bassett1,2,3,4,5§, Mingshu Huang2,3,4,6, Christie Cloete7, Sue Candy8, Janet Giddy7, Simone C Frank2,3, Kenneth A Freedberg1,2,3,4,5,9, Elena Losina3,4,5,10,11, Rochelle P Walensky1,2,3,4,5 and Robert A Parker3,4,5,6

Correspondence: Ingrid V Bassett, Massachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, Massachusetts 02114. Tel +1 617 726 0637. (ibassett@mgh.harvard.edu)

These data were presented in part at the 21st International AIDS Conference (AIDS 2016) 18 to 22 July 2016 in Durban, South Africa.

Abstract

Introduction: Changes to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) funding have led to closures of non-governmental HIV clinics with patient transfers to government-funded clinics. We sought to determine the success of transfers in South Africa using a national data source.

Methods: All adults (≥18 years) on antiretroviral therapy (ART) who visited a single PEPFAR-funded hospital-based HIV clinic in Durban, South Africa from March to June 2012 were transferred to community-based clinics. Previously, we matched patient records from the hospital-based HIV clinic with National Health Laboratory Services (NHLS) Corporate Data Warehouse (CDW) data to estimate the proportion of patients with a CD4 count or viral load (VL) in the CDW during the year before transfer. As a proxy for retention in care, in this study we evaluated whether patients had a CD4 count or VL at another facility within approximately three years of transfer. Patients referred to a private doctor at transfer were excluded from the analysis. We assessed predictors (age, sex, CD4 count, VL status, ART duration and location of future care) of not having post-transfer laboratory data using Cox proportional hazards models.

Results: Of the 3893 patients referred to a government facility at transfer, 41% were male and median age was 39 years (IQR 34 to 46). There was a post-transfer CD4 count or VL from another facility for 23% of these individuals within six months, 44% within two years and 61% within approximately three years. Male sex (aHR 1.20, 95% CI 1.10 to 1.31) and shorter duration on ART (<3 months, aHR 3.80, 95% CI 2.77 to 5.21; three months to one year, aHR 1.32, 95% CI 1.15 to 1.51, each compared with >1 year) were associated with not having a post-transfer record.

Conclusions: Using data from the NHLS CDW, 61% of patients had evidence of a post-transfer laboratory record at another facility within approximately three years after closure of a large South African HIV clinic. Males and those with shorter time on ART prior to transfer were at highest risk for lacking follow-up laboratory data. As patients transfer care, national data sources can be used to evaluate long-term patient care trajectories.

Keywords: South Africa; National Health Laboratory Service; patient transfers; community-based clinics; CD4 and viral load data; retention in care; transfer of HIV care

Received 25 July 2018; Accepted 22 May 2019

Copyright © 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

South Africa has the largest HIV treatment programme in the world, with more than 3.1 million people on antiretroviral therapy (ART) [1]. Because of a gradual, planned funding reduction from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to promote transition to full country-led fiscal responsibility, the South African government has continued to expand its national programme [2-6]. As part of this expansion, patient care has shifted from hospital-based, doctor-managed clinics towards nurse-led, public sector community clinics, resulting in large-scale patient transfers [7,8].

The clinical implications of patient transfers are difficult to assess, but have become increasingly important as the South African government focuses on strategies to improve linkage to and retention in HIV care [9,10]. Limited available data show similar clinical outcomes for those transferred to primary health clinics compared with hospital-based clinics [11-13]. However, these studies reflect outcomes of selected, clinically stable patients referred to community programmes [14-16]. In extant studies, receiving clinic nurses were provided with additional training in the context of a clinical trial, the sickest patients were still cared for by physicians, and a substantial fraction of patients refused the referral [12,14].
Strategies for evaluating linkage to and retention in community clinic care under “real world” programmatic conditions will prove invaluable for designing programmes that maximize continuity of clinical HIV care following transfers.

Data from the National Health Laboratory Service (NHLS), South Africa’s repository for all public sector laboratory measurements, have previously been used to evaluate the effectiveness of certain government-funded HIV-programmes [17-19], to identify patterns of the country’s TB epidemic [20,21], and to determine cancer incidence rates among HIV-infected patients [22]. While we have previously assessed the completeness and accuracy of the NHLS Corporate Data Warehouse (CDW) and have validated the NHLS CDW as a reliable data source [23], the use of NHLS data to evaluate the outcome of patient transfers has been limited [24]. Despite that, it has been shown to be an effective tool for more accurately estimating lost to follow-up for women transferring to postpartum care [25,26]. With its large size and comprehensive coverage (>80%) of the population [17,27], the NHLS CDW could serve as an important tool for tracking patients following healthcare facility closures or other care transfers. As programmes across South Africa continue to transfer patients from non-governmental organizations to government-funded, community clinics, identifying methods to inform the success of these transfers is critical.

Following a large-scale transfer from a physician-run, hospital-based, PEPFAR-funded HIV programme in Durban to nurse-led, community-based clinics, we sought to demonstrate the utility of NHLS data to evaluate success of transfer and to determine predictors of slower re-linkage to care.

2 | METHODS

2.1 | Study site

McCord Hospital was a semi-private, general hospital in Kwa-Zulu-Natal serving a predominantly urban population from the greater Durban area. The Sinikithemba HIV clinic at McCord, which became a PEPFAR-funded site in 2004, was an integral part of the South African ART scale-up and initiated over 10,000 patients on ART [28]. Sinikithemba served a predominantly African, Zulu-speaking population. Patients were seen by both nurses and doctors who were available for daily consultations and took on medically complex cases. The clinic was considered a local Center of Excellence and had a monitoring and evaluation team and an electronic medical record. Due to loss of PEPFAR funding, the clinic closed in June 2012.

All patients who returned to the clinic for clinical appointments, laboratories or pharmacy refills to Sinikithemba between 12 March 2012 and 30 June 2012, the “transfer period,” were referred for transfer to one of 171 different clinics in the Durban area. Patients taking first-line ART were transferred to primary healthcare clinics (PHC); those taking second-line ART were transferred to community health clinics (CHC), which provided a higher level of services than PHCs. Patients with comorbidities requiring medications not on the South African Essential Drug List were referred to hospital-based clinics. Data collected by the clinic at the time of transfer included sex, age, most recent CD4 count and viral load (VL) prior to transfer, and the type of clinic to which the participant were referred. We have previously reported on the Sinikithemba transfer process evaluating linkage to the initial transfer clinic visit and patient attitudes about their transfer experience using telephone surveys combined with validated clinic visits [28,29]. The current study seeks to assess linkage to HIV care post-transfer using availability of CD4 or VL testing within approximately three years of transfer as a proxy for successful transfer.

2.2 | Study population

The study population included adults on ART who visited the Sinikithemba HIV clinic during the transfer period. Patients <18 years old on 30 June 2012 were excluded, as we focused on the adult transfer process. For the post-transfer linkage assessment, we excluded patients who were referred to a private doctor, because we did not expect these individuals to have laboratory data in the NHLS system. Participants provided verbal consent for study participation at the time of transfer. The study protocol was approved by the McCord Hospital Research Ethics Committee (Durban, South Africa) and the Partners Human Research Committee (2012-P-001,122/1, Boston, MA).

2.3 | National Health Laboratory Service

The National Health Laboratory Service was established in 2001 and supports national and provincial health departments in South Africa. It is the largest diagnostic pathology service in the country, providing laboratory and related public health services to over 80% of the population through a national network of 265 laboratories [17]. The NHLS performs all public sector CD4 count and VL monitoring and maintains a Corporate Data Warehouse (CDW) that serves as a national repository for laboratory data from the public sector. Healthcare workers at each public health facility complete laboratory requisition forms which accompany each sample submitted to the CDW. All data, including patient identifiers, name of facility, date of sample and tests requested, are sent to the CDW and are captured electronically by the NHLS information system in real time. We have previously evaluated the completeness and accuracy of the NHLS CDW using a novel data crossmatching method [23].

2.4 | Data collection and processing

We sought to estimate the cumulative frequency of linkage using evidence of post-transfer CD4 count and VL after 30 June 2012. We sent a list of all 4257 McCord Hospital transfer patients with corresponding identifiers (patient ID, first name, surname, sex, date of birth, South African ID) to the NHLS to obtain laboratory records within approximately three years of the transfer (the last NHLS records extracted were in June 2015). To assist with the matching process, we also sent the last known CD4 count and VL values and dates recorded in the electronic medical record at McCord Hospital. From the original 4257 patient list, duplicated patient IDs (n = 12), patients <18 years old on 30 June 2012 (n = 337), and patients referred to private clinics (n = 15) were removed from the data sets prior to matching, resulting in a cohort of 3893 transfer patients for potential matching with NHLS laboratory data. Although laboratory monitoring recommendations have changed over time, laboratory monitoring of some kind (CD4 or VL or both) have been recommended every six or...
twelve months in South Africa for the duration of the study period.

We assessed deaths by cross-matching patients with the South African National Population Register using South African Identification Numbers in May 2014. Valid South African Identification Numbers were available for 94% of patients. More than 90% of deaths nationwide are captured in this register [30].

2.5 | Assessment of cumulative frequency of linkage after transfer

As we reported previously, after extensive efforts assessing the quality of subject matching for data provided by the NHLS, we determined that 99.7% of the individuals were correctly matched [23]. Based on this result, we previously recommended that matches from NHLS be accepted without extensive review, and have followed this approach in the current analysis [23]. Patients who had at least one NHLS record, whether CD4 count or VL, within approximately three years after the end of the transfer period were considered re-linked. We also assessed re-linkage rates at six months, one year and two years after the end of the transfer period.

2.6 | Statistical analysis

Standard life table methods were used in the analysis. Proportions linked at various time periods after the end of the transfer period were estimated using Kaplan-Meier methods. We used a Cox proportional hazards model to examine the hazard ratio of slower time to re-linkage (having no post-transfer measurements in the CDW over time). Predictors considered included sex, age, CD4 count at transfer (three levels: <200/µL; 200 to 500/µL; and >500/µL), virological suppression pre-transfer (three categories: suppressed, defined as NHLS coding of <400 copies/µL; not suppressed; and no VL data available), duration on ART prior to transfer (three categories: <3 months; three months to one year; and >1 year) and type of transfer facility. We excluded a total of 44 individuals with missing values for CD4 (3 individuals), ART duration (23 individuals), or missing location of future care (21 missing); several individuals were missing data on more than one variable. We retained missing VL as a separate category, due to the large number of missing records (298). We calculated hazard ratios (HR) with 95% confidence intervals (CI) for each individual factor. We then developed a multivariable model including all factors other than VL that were statistically significant in the univariate analysis and calculated adjusted hazard ratios (aHR). The goal of the model was to identify factors associated with higher risk of failure to re-link to care after clinic transfer to help guide programmes when considering which patients may be higher risk for LTFU post transfer. Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC).

3 | RESULTS

3.1 | Cohort characteristics

Of the 3893 participants included in the analysis, 41% of the cohort was male and median age was 39 (interquartile range (IQR) 34 to 46) (Table 1). The majority of patients had CD4 counts above 200/µL at transfer (<200/µL 16%, 200 to 500/µL 56%, >500/µL 29%) and 98% of patients with available VL data were virologically suppressed. As 298 patients (8%) did not have a VL available, however, the proportion known to be suppressed is only 90%. Among all participants, over 80% had been on ART for more than a year upon transfer (<3 months 5%, three months to one year 13%, >1 year 82%). Most patients were transferred to public sector clinics (PHC 67%, CHC 21%, hospital 12%). Fifteen patients (0.4%) were assigned to private doctors and were excluded as we did not expect that they would have laboratory tests through the NHLS. Eighty-four patients (2.2%) are known to have died after transfer but are included in our population for assessing re-linkage to care after transfer based on the availability of NHLS laboratory testing after the transfer period.

3.2 | Cumulative frequency of linkage to care over time

Among the 3893 patients transferred, 61% (2377) of these patients were re-linked to care by the end of our study period (Figure 1). Twenty-three percent were linked within six months of the end of the transfer period, 44% were linked within one year of the transfer period and 57% were linked within two years of the end of the transfer period. Among the 84 patients known to have died, 33

| Table 1. Characteristics of patients transferred from McCord Hospital to community-based clinics in Durban, South Africa |
|---------------------------------------------|--------|
| Patient characteristic                      | Total N = 3893 |
| Sex (male), N (%)                            | 1586 (41) |
| Age, median (IQR)                            | 39 (34 to 46) |
| CD4 count at transfer, N (%)b                | 406 (10) |
| <200/µL                                      | 606 (16) |
| 200 to 500/µL                                | 2164 (56) |
| >500/µL                                      | 1120 (29) |
| Viral load, % known suppressed at transfer, N (%)b | 3514 (90) |
| Duration of ART treatment, N (%)c            | 186 (5) |
| <3 months                                    | 523 (13) |
| 3 months to 1 year                           | 3161 (82) |
| >1 year                                      | 2609 (67) |
| Location of future care, N (%)d              | 811 (21) |
| Primary healthcare clinic                    | 452 (12) |
| Community health clinic                      | 84 (2) |
| Hospital-based clinic                        | 296 (7)

ART, antiretroviral therapy.

bBased on the last CD4 count value taken at McCord excluding three missing values; cBased on the last viral load value taken at McCord, with 298 missing values treated as not suppressed; dB-Based on the total time in years between the ART initiation date and the transfer date excluding 23 missing values; dBased on the total time in years between the ART initiation date and the transfer date excluding 23 missing values; eExcluding 21 “unknown” locations of future care.
(39%) had NHLS laboratory data after transfer and before death.

3.3 Predictors of slower re-linkage to care

In the unadjusted analyses, male sex (hazard ratio 1.19 (1.09 to 1.30)), age <30 (compared to age ≥30 years, hazard ratio 1.27 (1.10 to 1.47)), CD4 count <200/µL (compared to >500/µL, hazard ratio 1.38 (1.20 to 1.58), and shorter duration of ART (<3 months hazard ratio 3.96 (2.90 to 5.40) and three months to one year hazard ratio 1.35 (1.19 to 1.54), both compared to >1 year) were associated with slower re-linkage over time (Table 2). Missing VL data were a significant predictor of slower linkage (hazard ratio 3.31 (2.63 to 4.17)) but lack of suppression was not an important predictor (hazard ratio 1.12 (0.83 to 1.51)). The type of clinic to which participants were referred at transfer was also not associated with failure to re-link.

3.3.1 Multivariable model

Because only lack of VL data, strongly associated with shorter duration on ART (data not shown) was a significant predictor of slower linkage, VL was not included in the multivariable model. Males were more likely to be unlinked (adjusted hazard ratio 1.20 (1.10 to 1.31)) but age and CD4 count were no longer significant predictors (both \( p > 0.10 \)) (Table 2). Being on ART for a shorter duration at transfer (<3 months, adjusted hazard ratio 3.80 (2.77 to 5.21); three months to one year, adjusted hazard ratio 1.32 (1.15 to 1.51), each compared to >1 year) also increased the hazard of not being linked.

4 DISCUSSION

We assessed CD4 count or VL testing as a proxy for successful transfer of HIV care following a large-scale transfer from Mccord Hospital in Durban to nurse-led, community-based clinics by obtaining patient data from the NHLS CDW. We found that 2377 of the 3893 patients eligible for post-transfer assessment (61%) had evidence of a post-transfer follow-up visit based on NHLS CD4 count and VL data at approximately three years. We consider 61% to be a low estimate, based on the 221 who reported transferring to a private doctor in our prior study [28]. These findings are consistent with systematic reviews estimating 70% retention in care at 24 months among patients on ART in sub-Saharan Africa [31,32]. A more recent review focusing on retention in care between 2008 and 2013 in South Africa estimated an 18-month retention rate of 71% [33]. While these rates are comparable with our estimate, these studies do not exclusively focus on cohorts of transferred or “down-referred” patients who may face greater risks of disruption of care and loss to follow-up. However, our estimate is also consistent with a study evaluating national retention in South Africa’s HIV programme accounting for patient transfers estimating a 63%
A total of 44 individuals (24 linked; 20 not linked) were excluded for missing one or more of CD4, ART duration, or location of future care. ART, antiretroviral therapy; CDW, Corporate Data Warehouse; NHLS, National Health Laboratory Service; ref, reference group.

...has shown that males typically have worse outcomes than females at every step of the HIV care cascade [34,35]. Male sex has emerged as a predictor of poor retention in care in a number of settings in sub-Saharan Africa [32]; our finding that male sex is associated with higher risk of not having a post-transfer record in the NHLS CDW is consistent with these data.

In the ART duration adjusted model, spending <3 months on ART prior to transfer substantially increased the risk of not having a post-transfer record. As detectable viral load was not a predictor of slower linkage, and missing VL information was strongly associated with transfer within three months of starting ART, ART duration, rather than viral suppression, may be a more appropriate measure for defining “high risk” transfer patients.

There are several limitations to using national laboratory data as a marker of cumulative frequency of linkage to care. Our results are an estimate of patients who re-linked to care following transfer from McCord Hospital. This estimate is lower and may be more accurate than our previous estimate of 82%, which was based on patient self-report of re-linkage and validation of an initial clinic visit for a subset of patients [28]. We have previously assessed the completeness and accuracy of the NHLS CDW by matching patient identifiers and pretransfer CD4 and VL test results from the McCord Hospital dataset to data returned by NHLS; we reported that NHLS did not find a match for 10% of the patients in the transfer cohort [23], which may have also affected the ability to match post-transfer laboratories for a small proportion of patients. It is also possible that patients in care post-transfer were classified as “not re-linked” because they were not receiving guideline concordant CD4 count and VL monitoring at their new clinical site. Additionally, many more patients reported attending private sector clinics than were assigned to them at the time of transfer. If these private clinics used private laboratories, then these patients would not be expected to have CD4 count and VL data in the NHLS system even if they had linked to care. Removing these individuals from our potential pool would lead to a higher linkage rate. By focusing on laboratory data, we were unable to examine the reasons for gaps in linkage or to assess the quality of care received. The truncated ascertainment of outcomes and the fact that participants were on ART at transfer may explain the relatively low rate of mortality in the setting of a low rate of re-linkage.

Despite the drawbacks of this methodology, this study has several important strengths. Using NHLS data can transcend the limitations of collecting and analysing data within individual programmes, which presents challenges such as...

---

**Table 2. Predictors of not having post-transfer measurement data in the NHLS CDW**

| Patient characteristic | Linked N = 2353 (61%) | Not linked N = 1496 (39%) | Hazard ratio (95% CI) | Adjusted hazard ratio model (95% CI)* |
|------------------------|-----------------------|---------------------------|-----------------------|-------------------------------------|
| Sex (male), N (%)      | 901 (38)              | 672 (45)                  | 1.19 (1.09 to 1.30)   | 1.20 (1.10 to 1.31)                 |
| Age <30, N (%)         | 210 (9)               | 187 (13)                  | 1.27 (1.10 to 1.47)   | 1.12 (0.96 to 1.30)                 |
| CD4 count at transfer, N (%) |           |                           |                      |                                     |
| <200/µL                | 310 (13)              | 294 (20)                  | 1.38 (1.20 to 1.58)   | 1.04 (0.90 to 1.20)                 |
| 200 to 500/µL          | 1329 (57)             | 807 (54)                  | 1.07 (0.97 to 1.18)   | 0.98 (0.89 to 1.08)                 |
| >500/µL                | 714 (30)              | 395 (26)                  | ref                   | ref                                 |
| Viral load, N (%)      |                       |                           |                      |                                     |
| Suppressed at transfer | 2233 (95)             | 1244 (83)                 | ref                   | ref                                 |
| Not suppressed at transfer | 45 (2)               | 33 (2)                    | 1.12 (0.83 to 1.51)   | –                                   |
| Missing                | 75 (3)                | 219 (15)                  | 3.31 (2.63 to 4.17)   | –                                   |
| ART duration, N (%)    |                       |                           |                      |                                     |
| <3 months              | 41 (2)                | 144 (10)                  | 3.96 (2.90 to 5.40)   | 3.80 (2.77 to 5.21)                 |
| 3 months to 1 year     | 270 (11)              | 246 (16)                  | 1.35 (1.19 to 1.54)   | 1.32 (1.15 to 1.51)                 |
| >1 year                | 2042 (87)             | 1106 (74)                 | ref                   | ref                                 |
| Location of future care, N (%) |        |                           |                      |                                     |
| Primary healthcare clinic | 1567 (67)           | 1029 (69)                 | ref                   | –                                   |
| Community health clinic | 510 (22)             | 295 (20)                  | 0.94 (0.85 to 1.04)   | –                                   |
| Hospital-based clinic  | 276 (12)              | 172 (11)                  | 0.92 (0.81 to 1.06)   | –                                   |

A total of 44 individuals (24 linked; 20 not linked) were excluded for missing one or more of CD4, ART duration, or location of future care. ART, antiretroviral therapy; CDW, Corporate Data Warehouse; NHLS, National Health Laboratory Service; ref, reference group.

*Model adjusted for sex, age, CD4 count at transfer, and time on ART prior to transfer.*
differences in record-keeping methods and marked variability in how patients are identified. The ability to accurately classify “lost to follow-up” patients as having actually transferred care elsewhere is important for evaluating the quality of the national governmental ART programme, especially as known Centers of Excellence have been disbanded [36,37]. The NHLS CDW is centralized, comprehensive and offers wide coverage of public clinics across the country; it therefore represents a useful tool for helping track patients who change their service provider.

5 | CONCLUSIONS

The cumulative frequency of linkage to care after large-scale patient transfers is difficult to assess but has become increasingly important as PEPFAR funding in South Africa decreases and patient care transitions to public sector community clinics. We found that a national data set collected for clinical purposes may be used for evaluating linkage of individual patients within public, government-funded clinics. This ability to track patients may not only aid in the evaluation of re-linkage and retention outcomes following HIV-clinic closures and patient transfers but may also serve as an effective method to study patient flow and movement more generally within the HIV care system in South Africa, such as following transfer to postpartum HIV care. Additionally, this study utilizes NHLS data in a novel way. While NHLS CDW data have been used in several longitudinal cohort studies involving South Africa’s National Cancer Registry [22]. This methodology may be useful in the assessment of similar large-scale transfers in other sub-Saharan African countries with PEPFAR-funded clinics and national electronic laboratory databases [38]. For those who fail to link after transfer, these data could also direct efforts to reinforce linkage and avoid the morbidity and mortality associated with interruptions in care.

AUTHORS’ AFFILIATIONS

1Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; 2Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA; 3Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 4Harvard University Center for AIDS Research (CFAR), Boston, MA, USA; 5Harvard Medical School, Boston, MA, USA; 6Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; 7McCord Hospital, Durban, South Africa; 8Department of Academic Affairs, Research and Quality Assurance, Corporate Data Warehouse, National Health Laboratory Services, Johannesburg, South Africa; 9Departments of Epidemiology and Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA; 10Departments of Biostatistics and Epidemiology, Harvard University School of Public Health, Boston, MA, USA; 11Division of Rheumatology, Department of Medicine, and Department of Orthopedic Surgery, Brigham and Women’s Hospital, Boston, MA, USA

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHORS’ CONTRIBUTIONS

All authors have contributed significantly to this work and have reviewed and approved of this manuscript. IVB, Principal Investigator of this project, led the design and execution of this study as well as all stages of manuscript writing and preparation. MH and RAP led all data analysis efforts. MH initially helped to conduct the preliminary data analysis, while RAP collaboratively refined the analysis presented in the manuscript. RAP also contributed substantially and oversaw all method and analysis development. CC and JG both played significant roles in initial data collection and the procurement of records from McCord Hospital. SC also played a significant role in the procurement of CD4 and viral load records from the National Health Laboratory Services, which were used in the data crossmatch. EL, KAF, and RPW provided consultation during analysis development and contributed to manuscript editing and review. Additionally, EL provided biostatistical consultation. SCF, the Research Assistant, contributed significantly to manuscript writing, editing, and review.

ACKNOWLEDGEMENTS

We gratefully acknowledge the extensive efforts of the clinical and research teams at SSKhetha for providing strong leadership during a time of challenging transition. We thank Bridget Bunda for her work on the manuscript.

FUNDING

This work was supported by the National Institutes of Health (R01 MH108427 and R01 MH090326-03S1) and the Harvard University Center for AIDS Research (P30 AI060354), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAD, NCI, NICHD, NIDCR, NHLBI, NIDA, NIMH, NIA, NIDDK, NIGMS, NIMHD, FIC, and OA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Bassett was also supported by the Weissman Family MGH Research Scholar Award.

REFERENCES

1. How AIDS changed everything – MDG 6: 15 years, 15 lessons of hope from the AIDS response. UNAIDS. 2015.
2. Country ownership for a sustainable AIDS response: From principles to practice. UNAIDS. 2012.
3. Collins C, Beyrer C. Country ownership and the turning point for HIV/AIDS. Lancet Glob Health. 2013;16:e319–20.
4. Evaluation of PEPFAR - brief report. Institute of Medicine. 2013.
5. Bekker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boule A, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19 Suppl 3:105–16.
6. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2010;7(6): e1000296.
7. The South African Antiretroviral Treatment Guidelines. 2013.
8. Katz IT, Bassett IV, Wright AA. PEPFAR in transition – implications for HIV care in South Africa. N Engl J Med. 2013;369(15):1385–7.
9. National Strategic Plan on HIV, STIs and TB, 2012-2016. 2012.
10. National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents, and Adults. National Department of Health, South Africa; 2015.
11. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet. 2012;380(9845):889–98.
12. Humphreys CP, Wright J, Walley J, Manwura CT, Bailey KA, Ntshalingthshi SN, et al. Nurse led, primary care based antiretroviral treatment versus hospital care: a controlled prospective study in Swaziland. BMC Health Serv Res. 2010;10(1):229.
13. Auld AF, Kamiru H, Azih C, Baughman AL, Nuwagaba-Biribonwoha H, Ehrenkranz P, et al. Implementation and operational research: evaluation of Swaziland’s hub-and-spoke model for decentralizing access to antiretroviral therapy services. J Acquir Immune Defic Syndr. 2015;70(1):e1–12.
14. Brennau AT, Long L, Maskew M, Sanne I, Jaffray I, MacPhail P, et al. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011;25(16):2027–36.
15. Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8(7): e1001055.
16. O’Connor C, Osih R, Jaffer A. Loss to follow-up of stable antiretroviral therapy patients in a decentralized down-referral model of care in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2011;58(4):429–32.
17. Sherman GG, Lilian RR, Bhardwaj S, Candy S, Barron P. Laboratory information system data demonstrate successful implementation of the prevention of mother-to-child transmission programme in South Africa. S Afr Med J. 2014;104 3 Suppl 1:235–8.

18. Leon N, Mathews C, Lewin S, Osler M, Boule A, Lombard C. A comparison of linkage to HIV care after provider-initiated HIV testing and counselling (PTC) versus voluntary HIV counselling and testing (VCT) for patients with sexually transmitted infections in Cape Town, South Africa. BMC Health Serv Res. 2014;14:350.

19. Hsiao NY, Stinson K, Myer L. Linkage of HIV-infected infants from diagnosis to antiretroviral therapy services across the Western Cape, South Africa. PLoS One. 2013;8(2):e55308.

20. Dlamini-Mvelase NR, Werner L, Phili R, Cele LP, Mlisana KP. Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infect Dis. 2014;14:442.

21. McLaren ZM, Brouwer E, Ederer D, Fischer K, Branson N. Gender patterns of tuberculosis testing and disease in South Africa. Int J Tuberc Lung Dis. 2015;19(1):104–10.

22. Sengayi M, Spoerri A, Egger M, Kielkowski D, Crankshaw T, Cloete C, et al. Record linkage to correct under-ascertainment of cancers in HIV cohorts: the Sinikithemba HIV clinic linkage project. Int J Cancer. 2016;139 (6):1209–16.

23. Bassett IV, Huang M, Cloete C, Candy S, Giddy J, Frank SC, et al. Assessing the completeness and accuracy of South African National Laboratory CD4 and viral load data: a cross-sectional study. BMJ Open. 2018;8(8):e021506.

24. Fox MP, Bor J, Brennan AT, MacLeod WB, Maskew M, Stevens WS, et al. Estimating retention in HIV care accounting for patient transfers: a national laboratory cohort study in South Africa. PLoS Med. 2018;15(6):e1002589.

25. Cloete IV, Brouwer E, Ederer D, Fischer K, Branson N. Gender patterns of tuberculosis testing and disease in South Africa. Int J Tuberc Lung Dis. 2015;19(1):104–10.

26. Phillips TK, Clouse K, Zerbe A, Abrams EJ, Myer L. Linkage to care, mobility and retention of HIV-positive postpartum women in antiretroviral therapy services in South Africa. J Int AIDS Soc. 2018;21(54):e25114.

27. Corbett EL, Bandason T, Duong T, Dauya E, Makumure B, Churchyard GJ, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;376(9748):1244–53.

28. Cloete C, Regan S, Giddy J, Govender T, Erlwanger A, Gaynes MR, et al. The linkage outcomes of a large-scale, rapid transfer of HIV-infected patients from hospital-based to community-based clinics in South Africa. Open Forum Infect Dis. 2014;1(2):ofu058.

29. Katz IT, Bogart LM, Cloete C, Crankshaw TL, Giddy J, Govender T, et al. Understanding HIV-infected patients’ experiences with PEPFAR-associated transfers at a Centre of Excellence in KwaZulu Natal, South Africa: a qualitative study. AIDS Care. 2015;27:1–6.

30. Cornell M, Lescells R, Fox MP, Garone DB, Giddy J, Fenner L, et al. Mortality among adults transferred and lost to follow-up from antiretroviral therapy programmes in South Africa: a multicenter cohort study. J Acquir Immune Defic Syndr. 2014;67(2):e67–75.

31. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1:1–15.

32. Geng EH, Nash D, Kambugu A, Zhang Y, Braithstein P, Christopoulos KA, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7 (4):234–44.

33. (HE2RO) HEaERO. Retention on Antiretroviral Therapy in South Africa: Evidence from a Systematic Review 2008-2013. Wits Health Consortium, University of the Witwatersrand; 2014.

34. Bor J, Rosen S, Chimbindi N, Haber N, Herbst K, Mutevedzi T, et al. Mass HIV treatment and sex disparities in life expectancy: demographic surveillance in rural South Africa. PloS Med. 2015;12(11):e1001905.

35. Croce-Galis M, Gay J, Hardee K. Gender considerations along the HIV treatment cascade: an evidence review with priority actions. The evidence project. Washington, D.C.: What Works Association, The Population Council; 2015.

36. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr. 2013;63(2):e64–71.

37. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2013;63(3):405–11.

38. Lecher S, Ellenberger D, Kim AA, Fonjungo PN, Agolory S, Borget MY, et al. Scale-up of HIV viral load monitoring–seven Sub-Saharan African countries. MMWR Morb Mortal Wkly Rep. 2015;64(46):1287–90.